Nepal | January 15, 2021

Sinovac’s COVID-19 vaccine 78% effective in late-stage trial in Brazil

reuters
Share Now:

SAO PAULO: A COVID-19 vaccine developed by China’s Sinovac Biotech was 78% effective in a late-stage Brazilian trial, a person familiar with the study said on Thursday, moving the shot closer to regulatory approval in South America’s biggest country.

The results, closely watched by developing countries counting on the vaccine to begin mass inoculations, come after Turkish researchers said in December that the vaccine showed 91.25% efficacy based on interim data.

Brazil and Indonesia, which have the most COVID-19 cases in Latin America and Southeast Asia respectively, are preparing to roll out the vaccine, called CoronaVac, this month.

Although Coronavac’s efficacy trails the more than 90% success rate of vaccines from Moderna Inc or Pfizer Inc and its partner BioNTech SE, it is easier to transport and can be stored at normal refrigerator temperatures.

Turkey, Chile, Singapore, Ukraine and Thailand have also struck supply deals with Sinovac.

The company’s Brazilian partner, biomedical center Butantan, presented the efficacy data to federal health regulator Anvisa in a Thursday morning meeting seeking approval for emergency use of the vaccine, according to the source who spoke anonymously because the results are not yet public.

The findings, first reported by newspaper Folha de S.Paulo, are based on a study led by Butantan involving about 13,000 volunteers, with half receiving a placebo and half taking the two-dose vaccine.

China has at least five vaccines, developed by Sinovac, Sinopharm, CanSino Biologics and the Chinese Academy of Sciences, in late-stage trials, underscoring its efforts to develop a homegrown vaccine to challenge Western rivals.

Since the new coronavirus emerged a year ago in a market in the central Chinese city of Wuhan, President Xi Jinping has pledged to make China’s vaccines a global public good.

The positive data follows China’s approval on Dec. 31 of a vaccine developed by an affiliate of Sinopharm that showed 79.34% efficacy, pointing to progress China has made in the global race to develop successful vaccines.

Although China has been slower than several other countries in approving the vaccines, it has inoculated more than 2 million people since July under an emergency use program, using three different shots from Sinovac and Sinopharm that are still undergoing late-stage trials.

In Brazil, President Jair Bolsonaro has expressed disdain for the Sinovac vaccine, citing doubts about its “origin” and trading barbs with political rival João Doria, the governor of Sao Paulo, which is funding trials and production of the shot.

Brazil has the world’s second-deadliest outbreak after the United States and aims to vaccinate 51 million people, or about one-fourth of its population, in the first half of 2021, although immunizations have not yet begun.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

First Arab Ama Dablam Expedition makes successful attempt on Thursday

KATHMANDU: A team from Seven Summit Treks ‘First Arab Ama Dablam Expedition’ comprising Qatari climber Fahad Badar, Sherief Elabd from Eygpt and Nadhira Al Harthy from Oman have attempted Mt Ama Dablam (6812 m) on January 14. The winter ascent to Ama dablam consisted of at least 14 climbers w Read More...

215 new COVID-19 infections recorded in Kathmandu Valley on Thursday

KATHMANDU: The three districts of Kathmandu valley reported as many as 215 new cases of the coronavirus infection on Thursday. Of the total 403 new cases in the country, Kathmandu district reported 189 infections while Lalitpur and Bhaktapur registered 23 and three infections respectively. Cur Read More...

Nepal Covid Update: 403 new cases, 405 recoveries, six deaths on Thursday

KATHMANDU: Nepal’s Health Ministry shared the latest updates on coronavirus contagion from across the country. Till date, 2,002,041 tests through Polymerase Chain Reaction (PCR) method have been carried out wherein 5,032 tests were performed in the last 24 hours. Read Also: 215 new COVID-1 Read More...

Holders Bayern knocked out of German Cup by second tier Kiel

KIEL: Holders Bayern Munich twice gave up a one-goal lead before crashing out of the German Cup 6-5 on penalties to second tier Holstein Kiel on Wednesday following a 2-2 draw after extra time in the second-round match. Both sides converted all five spot-kicks before Bayern's Marc Roca had hi Read More...

England in control after bowling out Sri Lanka for 135 runs

GALLE: England captain Joe Root struck his 50th test fifty to put them in a strong position on the first day of the opening test after Dom Bess took five wickets as the tourists bowled out Sri Lanka for a paltry 135. An unbeaten 110-run partnership between Jonny Bairstow and Root saw England to 1 Read More...

English Premier League, Manchester United, Liverpool, Ander Herrera, Gerginio Wijnaldum

Man United's title aspirations set for Anfield acid test

LONDON: There have been a few false dawns but there is growing belief that Manchester United are on the cusp of reclaiming their place as the pre-eminent force in English football. They are top of the Premier League table after New Year's Day for the first time since Alex Ferguson's glittering dy Read More...

Vaccines due in weeks or months not yet Africa's way out of pandemic, officials say

ABUJA/JOHANNESBURG: Vaccines are not yet Africa's way out of the pandemic as it may be weeks or even months before first doses start to arrive, health officials said on Thursday, after the African Union (AU) secured 270 million doses for the continent where about 30,000 a day are becoming infected. Read More...

German vaccine institute praises efficacy of Astra-Oxford vaccine

FRANKFURT: The head of Germany's vaccine regulator on Thursday described the success rate of AstraZeneca's COVID-19 vaccine as excellent, after some Australian scientists voiced scepticism about its efficacy. Speaking during an online press briefing, the president of Germany's Paul Ehrl Read More...